文献速递技术与安全神经胸部CTMRPET

面向放射科医生的嵌合抗原受体T细胞治疗影像学入门

Imaging Primer on Chimeric Antigen Receptor T-Cell Therapy for Radiologists.
PubMed 文献 · Radiographics · 2022-01-01

嵌合抗原受体(CAR)T细胞治疗是复发或难治性B细胞淋巴瘤及儿童或成人急性淋巴细胞白血病的新治疗范式,缓解率超过80%,但可伴细胞因子释放综合征、免疫效应细胞相关神经毒性综合征及感染等毒性反应;部分毒性有影像学表现,熟悉其影像谱有助于避免误判。

要点

  • CAR T细胞治疗缓解率超过80%,疗效反应较常规化疗或免疫治疗更迅速,期间可伴短期水肿。
  • 治疗相关毒性常见细胞因子释放综合征、免疫效应细胞相关神经毒性综合征及免疫抑制相关感染。
  • 部分毒性影像学可见,部分影像学隐匿而需临床评估诊断,熟悉影像谱可避免误判。

核心结论

  • CAR T细胞治疗是复发或难治性B细胞淋巴瘤及儿童或成人急性淋巴细胞白血病的新治疗范式,熟悉其疗效演变和不良事件的影像谱及与治疗时间线的对应关系有助于优化患者管理。

研究设计与样本

  • 综述(Radiographics 入门综述),附在线补充材料和特邀评论。

关键影像表现/征象

  • 疗效反应较常规化疗或免疫治疗更迅速,治疗期间可伴短期水肿。
  • 部分治疗相关毒性具有影像学表现,熟悉其影像谱是避免误判的关键。
  • 其他临床毒性在影像上可能隐匿,需依据临床评估诊断。

临床应用与阅片要点

  • 了解CAR T细胞治疗预期疗效演变及潜在不良事件,并与治疗时间线相关联,以优化患者管理。
  • 熟悉治疗相关毒性的影像谱以避免误判;影像隐匿的毒性需依据临床评估诊断。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Chimeric antigen receptor (CAR) T-cell therapy is a recently approved breakthrough treatment that has become a new paradigm in treatment of recurrent or refractory B-cell lymphomas and pediatric or adult acute lymphoid leukemia. CAR T cells are a type of cellular immunotherapy that artificially enhances T cells to boost eradication of malignancy through activation of the native immune system. The CAR construct is a synthetically created functional cell receptor grafted onto previously harvested patient T cells, which bind to preselected tumor-associated antigens and thereby activate host immune signaling cascades to attack tumor cells. Advantages include a single treatment episode of 2-3 weeks and durable disease elimination, with remission rates of over 80%. Responses to therapy are more rapid than with conventional chemotherapy or immunotherapy, with intervening short-interval edema. CAR T-cell administration is associated with therapy-related toxic effects in a large percentage of patients, notably cytokine release syndrome, immune effect cell-associated neurotoxicity syndrome, and infections related to immunosuppression. Knowledge of the expected evolution of therapy response and potential adverse events in CAR T-cell therapy and correlation with the timeline of treatment are important to optimize patient care. Some toxic effects are radiologically evident, and familiarity with their imaging spectrum is key to avoiding misinterpretation. Other clinical toxic effects may be occult at imaging and are diagnosed on the basis of clinical assessment. Future directions for CAR T-cell therapy include new indications and expanded tumor targets, along with novel ways to capture T-cell activation with imaging. An invited commentary by Ramaiya and Smith is available online. Online supplemental material is available for this article. ©RSNA, 2022.

来源:Radiographics,查看原文。版权归原作者所有。

引用

  1. de Groot PM, Arevalo O, Shah K, et al. Imaging Primer on Chimeric Antigen Receptor T-Cell Therapy for Radiologists. Radiographics. 2022. PMID: 34990326. doi:10.1148/rg.210065

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。